TY - JOUR
T1 - Transient ST-elevation myocardial infarction versus persistent ST-elevation myocardial infarction. An appraisal of patient characteristics and functional outcome
AU - Janssens, Gladys N.
AU - Lemkes, Jorrit S.
AU - van der Hoeven, Nina W.
AU - van Leeuwen, Maarten A. H.
AU - Everaars, Henk
AU - van de Ven, Peter M.
AU - Brinckman, Stijn L.
AU - Timmer, Jorik R.
AU - Meuwissen, Martijn
AU - Meijers, Joost C. M.
AU - van der Weerdt, Arno P.
AU - ten Cate, Tim J. F.
AU - Piek, Jan J.
AU - von Birgelen, Clemens
AU - Diletti, Roberto
AU - Escaned, Javier
AU - van Rossum, Albert C.
AU - Nijveldt, Robin
AU - van Royen, Niels
N1 - Funding Information: This work was supported by unrestricted research grants from AstraZeneca and Biotronik. The collaboration was financed by the Ministry of Economic Affairs, The Netherlands by means of the PPP Allowance made available by the Top Sector Life Sciences & Health to stimulate public-private partnerships.Prof. dr. van Royen reports research grants from AstraZeneca, Abbott, Philips, Biotronik and a honorarium from Medtronic. Dr. Lemkes reports grants from Biotronik and Astrazeneca, during the conduct of the study. Prof. dr. Piek reports non-financial support from Abbott Vascular as member medical advisory board, personal fees and non-financial support from Philips/Volcano as Consultant, outside the submitted work. Prof. dr. von Birgelen reports institutional research grants from Abbott Vascular, Biotronik, Boston Scientific and Medtronic, outside the submitted work. Dr. van Leeuwen reports grants from AstraZeneca, grants from Top Sector Life Sciences & Health, during the conduct of the study. Dr. Escaned reports consultancies work for Philips, outside of the submitted work. All other authors declare no competing interests with regards to the study. Funding Information: Prof. dr. van Royen reports research grants from AstraZeneca , Abbott , Philips , Biotronik and a honorarium from Medtronic . Dr. Lemkes reports grants from Biotronik and Astrazeneca , during the conduct of the study. Prof. dr. Piek reports non-financial support from Abbott Vascular as member medical advisory board, personal fees and non-financial support from Philips/Volcano as Consultant, outside the submitted work. Prof. dr. von Birgelen reports institutional research grants from Abbott Vascular , Biotronik , Boston Scientific and Medtronic , outside the submitted work. Dr. van Leeuwen reports grants from AstraZeneca , grants from Top Sector Life Sciences & Health , during the conduct of the study. Dr. Escaned reports consultancies work for Philips, outside of the submitted work. All other authors declare no competing interests with regards to the study. Funding Information: This work was supported by unrestricted research grants from AstraZeneca and Biotronik . The collaboration was financed by the Ministry of Economic Affairs , The Netherlands by means of the PPP Allowance made available by the Top Sector Life Sciences & Health to stimulate public-private partnerships. Publisher Copyright: © 2021 The Author(s) Copyright: Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2021/8/1
Y1 - 2021/8/1
N2 - Background: Up to 24% of patients presenting with ST-elevation myocardial infarction (STEMI) show resolution of ST-elevation and symptoms before revascularization. The mechanisms of spontaneous reperfusion are unclear. Given the more favorable outcome of transient STEMI, it is important to obtain further insights in differential aspects. Methods: We compared 251 patients who presented with transient STEMI (n = 141) or persistent STEMI (n = 110). Clinical angiographic and laboratory data were collected at admission and in subset of patients additional index hemostatic data and at steady-state follow-up. Cardiac magnetic resonance imaging (CMR) was performed at 2–8 days to assess myocardial injury. Results: Transient STEMI patients had more cardiovascular risk factors than STEMI patients, including more arterial disease and higher cholesterol values. Transient STEMI patients showed angiographically more often no intracoronary thrombus (41.1% vs. 2.7%, P < 0.001) and less often a high thrombus burden (9.2% vs. 40.0%, P < 0.001). CMR revealed microvascular obstruction less frequently (4.2% vs. 34.6%, P < 0.001) and smaller infarct size [1.4%; interquartile range (IQR), 0.0–3.7% vs. 8.8%; IQR, 3.9–17.1% of the left ventricle, P < 0.001] with a better preserved left ventricular ejection fraction (57.8 ± 6.7% vs. 52.5 ± 7.6%, P < 0.001). At steady state, fibrinolysis was higher in transient STEMI, as demonstrated with a reduced clot lysis time (89 ± 20% vs. 99 ± 25%, P = 0.03). Conclusions: Transient STEMI is a syndrome with less angiographic thrombus burden and spontaneous infarct artery reperfusion, resulting in less myocardial injury than STEMI. The presence of a more effective fibrinolysis in transient STEMI patients may explain these differences and might provide clues for future treatment of STEMI.
AB - Background: Up to 24% of patients presenting with ST-elevation myocardial infarction (STEMI) show resolution of ST-elevation and symptoms before revascularization. The mechanisms of spontaneous reperfusion are unclear. Given the more favorable outcome of transient STEMI, it is important to obtain further insights in differential aspects. Methods: We compared 251 patients who presented with transient STEMI (n = 141) or persistent STEMI (n = 110). Clinical angiographic and laboratory data were collected at admission and in subset of patients additional index hemostatic data and at steady-state follow-up. Cardiac magnetic resonance imaging (CMR) was performed at 2–8 days to assess myocardial injury. Results: Transient STEMI patients had more cardiovascular risk factors than STEMI patients, including more arterial disease and higher cholesterol values. Transient STEMI patients showed angiographically more often no intracoronary thrombus (41.1% vs. 2.7%, P < 0.001) and less often a high thrombus burden (9.2% vs. 40.0%, P < 0.001). CMR revealed microvascular obstruction less frequently (4.2% vs. 34.6%, P < 0.001) and smaller infarct size [1.4%; interquartile range (IQR), 0.0–3.7% vs. 8.8%; IQR, 3.9–17.1% of the left ventricle, P < 0.001] with a better preserved left ventricular ejection fraction (57.8 ± 6.7% vs. 52.5 ± 7.6%, P < 0.001). At steady state, fibrinolysis was higher in transient STEMI, as demonstrated with a reduced clot lysis time (89 ± 20% vs. 99 ± 25%, P = 0.03). Conclusions: Transient STEMI is a syndrome with less angiographic thrombus burden and spontaneous infarct artery reperfusion, resulting in less myocardial injury than STEMI. The presence of a more effective fibrinolysis in transient STEMI patients may explain these differences and might provide clues for future treatment of STEMI.
KW - Cardiac magnetic resonance imaging
KW - Culprit vessel patency
KW - Fibrinolysis
KW - ST-elevation myocardial infarction
KW - Transient ST-elevation myocardial infarction
UR - http://www.scopus.com/inward/record.url?scp=85107374603&partnerID=8YFLogxK
U2 - https://doi.org/10.1016/j.ijcard.2021.05.018
DO - https://doi.org/10.1016/j.ijcard.2021.05.018
M3 - Article
C2 - 34004231
SN - 0167-5273
VL - 336
SP - 22
EP - 28
JO - International journal of cardiology
JF - International journal of cardiology
ER -